Arfysica Innovation
Brain-Computer Interface Technology Researcher
Brain-Computer Interface Financing Remains Hot! Recently, Shanghai Shuli Intelligent Technology Co., Ltd. (referred to as "Arfysica Innovation"), a leading enterprise in brain-computer interface technology, announced the completion of its C-round financing worth hundreds of millions of RMB. This round of financing was jointly invested by multiple institutions including Daohe Capital, Oriental Hengxin, and Xinding Capital, along with existing shareholders.
The financing funds will be used to continuously drive the generational leap of brain-computer interface technology, deepen diversified industrial applications, and build an innovative ecosystem covering multiple scenarios across the entire brain-computer interface chain. Notably, Arfysica Innovation disclosed the completion of a hundreds-of-millions-yuan B+ round of financing in mid-January, and announced another hundreds-of-millions-yuan C round of financing just one month later. Such密集 capital moves, with one round per month, are also rare in this field.
From Siemens Healthineers to the Frontline of Brain-Computer Interface Startups
It is reported that Arfysica Innovation has gathered top experts in brain science in China and a first-class interdisciplinary technical team of medicine and engineering. Among them, Dr. Wei Wang, the founder of Arfysica Innovation, who is from the "post-70s generation," holds double bachelor's degrees in biomedical engineering and economic law from Tianjin University, as well as a Ph.D. in biomedical engineering from the University of Southampton in the UK, during which she was awarded the ORS Scholarship by the British government.
Founder of Arfysica Innovation, Wang Wei
After graduation, Dr. Wei Wang joined Siemens Healthineers as a "Siemens Global Core Expert," leading the development of large-scale medical systems. She also served as an expert member of the IEC International Medical Equipment Standards Committee. This experience gave her a composite advantage in "engineering + standards + industrialization," with particular expertise in medical systems engineering and advancing international cooperation. In 2015, after returning to China to start her own business, she founded Arfysica Innovation and its series of subsidiaries, serving as the founder and chairman. She led her team in developing brain-computer interface and digital life technology products. Under her name, she holds more than a hundred domestic and international patents and concurrently serves in various industry association and research institution roles. She was also awarded the title of "Top 50 Young Innovators and Entrepreneurs in Shanghai" and recognized as a "Technology Leader in Shanghai," being selected for the "Shanghai Top 50 Young Innovators and Entrepreneurs Forum."
丨Deep Cultivation of Underlying Technologies, Closing the Industrialization Loop of Brain-Computer Interfaces
Arfysica Innovation, headquartered in Fengxian District, Shanghai, is a technology innovation enterprise focused on brain-computer interface and neuroengineering technologies. It is committed to providing digital solutions for clinical diagnosis and treatment through artificial intelligence and multimodal data. The company has a regional headquarters in Germany and has established a global R&D and production network in Beijing, Xi'an, Nanjing, Frankfurt, and other locations. Unlike single-point algorithm companies, Arfysica Innovation adheres to a "platformization + engineering" development path, completing a full closed loop from "theoretical research - clinical validation - product delivery - industrial implementation." The company has achieved independent breakthroughs in key technological nodes such as EEG signal sensors, brain-computer chips, decoding algorithms, and system integration.
The core advantage of the company lies in its self-developed "Artificial Intelligence Multimodal Brain-Computer Interface Platform," which deeply integrates non-invasive brain-computer interfaces, motor imagery paradigms, virtual reality (VR), and artificial intelligence algorithms, achieving a technical closed loop from multi-modal signal acquisition, real-time decoding to precise feedback in the human body.
Based on this platform, Arfysica Innovation has launched three core products:
1. Brain-computer interface active electrical stimulation system, which reads patients' motor intentions and converts them into electrical stimulation signals to guide neural pathway remodeling, achieving active rehabilitation;
Second, the brain-computer interface intelligent exoskeleton combines mind control with mechanical exoskeletons to assist patients with limb movement disorders in gait training.
Third, U-Resmart Full-cycle IntelligenceDigital HealthcareThe data management cloud platform, as a digital foundation, provides full-cycle management, analysis, and cloud storage services for medical data.
Currently, the company's product pipeline has covered multiple clinical fields such as limb movement disorders, consciousness and cognitive impairments, mental illnesses, and neurodevelopmental disorders. In addition, the company is exploring new directions such as mental illnesses, pediatric neurodevelopmental disorders, consumer-grade applications, and educational scenarios, striving to bring brain-computer interface technology "from the laboratory to families and society."
The profound R&D accumulation has also won Arfysica Innovation extensive industry recognition.
The company has been awarded the titles of "Little Giant" enterprise with specialized and sophisticated new technologies at the national level, National High-tech Enterprise, and "Science and Technology Little Giant" enterprise in Shanghai, and has established a municipal-level academician expert workstation. Meanwhile, Arfysica Innovation serves as the chairman unit of the Yangtze River Delta Branch of the Brain-Computer Interface Industry Alliance and is an executive director unit of the Brain-Computer Interface and Neuromorphic Intelligence Professional Committee of the China Standardization Association. In terms of intellectual property layout, the company owns more than 500 independent intellectual property rights.
丨Medical Rapid Implementation, Already Covering Multiple Tier-3 Hospitals in China
It is reported that Arfysica Innovation's product line has been applied in the neurosurgery, rehabilitation, and pediatrics departments of many Class A tertiary hospitals across China. It has not only established the first brain-computer interface ward and the first pediatric brain-computer interface diagnosis and treatment center in China, but also pioneered the "physician + engineer joint ward rounds" model, and built the first non-invasive brain-computer interface clinical research base, promoting the practical application and scaling of brain-computer interface technology in clinical scenarios.
Moreover, Arfysica Innovation and China General Technology Group jointly established the "Shanghai General Arfysica Brain Science Research Institute," aiming to create a globally influential brain science innovation hub. This not only gathers top-tier resources but also aspires to build a globally competitive brain science innovation center, driving the future transformation of smart healthcare.
丨First-tier capital continues to support, and the financing pace of brain-computer interface track accelerates
Under the multiple favorable conditions of China's "15th Five-Year Plan" forward-looking layout of future industries, the seven departments jointly issuing the "Implementation Opinions on Promoting the Innovative Development of Brain-Computer Interface Industry" to establish an action blueprint, and the breakthrough implementation of medical insurance payment policies, the brain-computer interface industry is ushering in an unprecedented strategic opportunity period. The continuous release of supportive policies provides a strong engine and a clear path for rapidly打通ing the industry closed loop of "technology research and development - clinical verification - commercialization landing."
As a typical representative of new quality productivity, brain-computer interfaces are accelerating their transition from laboratories to clinical applications and industrialization. According to industry analysis, the market size of China's medical-grade brain-computer interfaces reached 3.2 billion yuan in 2024 and is expected to grow to 5.58 billion yuan by 2027, with an average annual growth rate of around 20%. If consumer-grade products are included, the market potential over the next decade could exceed one trillion yuan.
Globally, the brain-computer interface market is also experiencing rapid growth, with expectations to rise from $2.14 billion in 2024 to $12.4 billion by 2034 — a nearly fivefold increase over a decade, representing an extremely rare growth curve in any industry.
In this rapidly growing emerging track, Arfysica Innovation continues to gain favor from top-tier capital.
Since completing its Series A financing in 2022, the company has successively completed its Series A+ and strategic investment rounds in 2024, followed by a Series B round in 2025. Entering 2026, it further completed both Series B+ and Series C financing rounds within just half a year, with cumulative funding reaching hundreds of millions of yuan.
Currently, the company has attracted several top-tier institutions such as Oriental Fortune, Daohe Investment, the National SME Development Fund, and New Ding Capital. The cumulative financing scale ranks among the top in China's non-invasive brain-computer interface field, fully demonstrating the capital market's high recognition of Arfysica Innovation's technical approach and its clinical penetration capabilities.
丨In Conclusion
Currently, brain-computer interfaces are in a critical window period transitioning from "clinical value validation" to "establishment of diagnostic and therapeutic pathways," and Arfysica Innovation is at the forefront of this industrial transformation.
Looking to the future, driven by the dual engines of securing a leading position in the medical-grade market and the burgeoning consumer-level blue ocean, Arfysica Innovation will continue to propel advancements in brain-computer interface technology. As founder Dr. Wang Wei stated: "Our goal is not only to secure a competitive edge for Chinese technology on the world stage but also to ensure that every technological breakthrough translates into products and hope that end users can readily access, enhancing the quality and brilliance of human life through technological leaps."